US Bancorp DE decreased its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 6.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 8,751 shares of the medical research company’s stock after selling 629 shares during the period. US Bancorp DE’s holdings in Bio-Rad Laboratories were worth $2,826,000 at the end of the most recent reporting period.
Several other hedge funds also recently bought and sold shares of BIO. Teacher Retirement System of Texas increased its position in Bio-Rad Laboratories by 2.5% during the third quarter. Teacher Retirement System of Texas now owns 1,711 shares of the medical research company’s stock worth $613,000 after buying an additional 41 shares in the last quarter. Assenagon Asset Management S.A. increased its position in Bio-Rad Laboratories by 230.3% during the third quarter. Assenagon Asset Management S.A. now owns 6,176 shares of the medical research company’s stock worth $2,214,000 after buying an additional 4,306 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in Bio-Rad Laboratories by 7.8% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 20,699 shares of the medical research company’s stock worth $7,420,000 after buying an additional 1,497 shares in the last quarter. Barclays PLC grew its position in shares of Bio-Rad Laboratories by 2.8% in the third quarter. Barclays PLC now owns 45,205 shares of the medical research company’s stock valued at $16,203,000 after purchasing an additional 1,245 shares during the period. Finally, Metis Global Partners LLC grew its position in shares of Bio-Rad Laboratories by 10.5% in the third quarter. Metis Global Partners LLC now owns 1,082 shares of the medical research company’s stock valued at $388,000 after purchasing an additional 103 shares during the period. Hedge funds and other institutional investors own 65.24% of the company’s stock.
Analysts Set New Price Targets
A number of equities research analysts have recently commented on the company. StockNews.com raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Tuesday. Royal Bank of Canada lowered their price target on Bio-Rad Laboratories from $484.00 to $480.00 and set an “outperform” rating for the company in a research report on Friday, February 16th. Citigroup downgraded Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and lowered their price target for the company from $400.00 to $365.00 in a research report on Wednesday, April 3rd. Finally, UBS Group lowered their price target on Bio-Rad Laboratories from $420.00 to $385.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $461.00.
Bio-Rad Laboratories Price Performance
Shares of NYSE BIO opened at $282.01 on Friday. Bio-Rad Laboratories, Inc. has a 1-year low of $261.59 and a 1-year high of $431.79. The business has a 50-day moving average of $299.92 and a 200-day moving average of $313.59. The company has a debt-to-equity ratio of 0.13, a current ratio of 6.57 and a quick ratio of 4.89. The company has a market capitalization of $8.04 billion, a price-to-earnings ratio of -27.22 and a beta of 0.94.
Bio-Rad Laboratories (NYSE:BIO – Get Free Report) last issued its earnings results on Tuesday, May 7th. The medical research company reported $2.29 earnings per share for the quarter, topping the consensus estimate of $2.04 by $0.25. Bio-Rad Laboratories had a positive return on equity of 3.59% and a negative net margin of 12.37%. The company had revenue of $610.82 million during the quarter, compared to the consensus estimate of $619.09 million. During the same quarter in the prior year, the business earned $3.34 earnings per share. The company’s revenue was down 9.8% compared to the same quarter last year. On average, equities analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.41 EPS for the current fiscal year.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.
See Also
Receive News & Ratings for Bio-Rad Laboratories Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bio-Rad Laboratories and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
